Manas Mishra has covered the healthcare and pharmaceuticals sector since 2017. He joined Norstella from Reuters, where he spent 8 years covering a range of breaking news stories ranging from vaccine development during the peak of the COVID-19 pandemic, to the killing of UnitedHealthcare CEO Brian Thompson. Manas was the Editor-in-Charge of the Bangalore health and pharmaceuticals team at Reuters between 2022-2025. When not looking for stories, Manas enjoys attending rock and metal concerts, swimming and reading science fiction.
Latest from Manas Mishra
Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.
Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.